The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia

Br J Haematol. 2018 Apr;181(1):137-139. doi: 10.1111/bjh.14508. Epub 2017 Feb 21.

Authors

Svitlana Demyanets¹, Eva Jaeger¹, Eleonore Pablik², Georg Greiner¹, Susanne Herndlhofer³, Peter Valent^{3

4}, Ilse Schwarzinger¹

Affiliations

¹ Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
² Centre for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
³ Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria.
⁴ Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.

PMID: 28220937
DOI: 10.1111/bjh.14508

No abstract available

Keywords: JAK2; chronic myeloid leukaemia; colony assay; inhibitor; progenitor cell growth.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Female
Humans
Janus Kinase 2 / antagonists & inhibitors*
Janus Kinase 2 / metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Male
Neoplasm Proteins / antagonists & inhibitors*
Neoplasm Proteins / metabolism
Neoplastic Stem Cells / enzymology*
Neoplastic Stem Cells / pathology
Pyrimidines / pharmacology*
Sulfonamides / pharmacology*

Substances

Neoplasm Proteins
Pyrimidines
Sulfonamides
TG101209
JAK2 protein, human
Janus Kinase 2